ReviewBrain pathology (Zurich, Switzerland)2016
Cerebral Perfusion Enhancing Interventions: A New Strategy for the Prevention of Alzheimer Dementia.
Review in Brain pathology (Zurich, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 49 citations in OpenAlex.
- Exploring Lymphovenous Anastomosis for Alzheimer Disease: Addressing Brain Lymphatic Dysfunction, Feasibility, and Outcome Metrics.Plastic and reconstructive surgery · 2026Review
- Abnormal Internal Carotid Artery Kinking in a Cadaver: Morphogenesis and a Potential Link to Alzheimer's Disease.Cureus · 2025Article
- Update on the Use of Pulse Wave Velocity to Measure Age-Related Vascular Changes.Current hypertension reports · 2024Review
- Prefrontal photobiomodulation produces beneficial mitochondrial and oxygenation effects in older adults with bipolar disorder.Frontiers in neuroscience · 2023Article
- Pathological changes within the cerebral vasculature in Alzheimer's disease: New perspectives.Brain pathology (Zurich, Switzerland) · 2022Review
- Epigenetic Studies in the Male APP/BIN1/COPS5 Triple-Transgenic Mouse Model of Alzheimer's Disease.International journal of molecular sciences · 2022Article
- Ischemia as a common trigger for Alzheimer's disease.Frontiers in aging neuroscience · 2022Article
- Low Flow and Microvascular Shunts: A Final Common Pathway to Cerebrovascular Disease: A Working Hypothesis.Advances in experimental medicine and biology · 2022Article
- Reduced parenchymal cerebral blood flow is associated with greater progression of brain atrophy: The SMART-MR study.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Type 2 diabetes mellitus-associated transcriptome alterations in cortical neurones and associated neurovascular unit cells in the ageing brain.Acta neuropathologica communications · 2021Article
- Neurologic and Immunologic Complications of COVID-19: Potential Long-Term Risk Factors for Alzheimer's Disease.Journal of Alzheimer's disease reports · 2020Article
- Photobiomodulation for Alzheimer's Disease: Translating Basic Research to Clinical Application.Journal of Alzheimer's disease : JAD · 2020Review
- Treating psychiatric symptoms and disorders with non-psychotropic medications .Dialogues in clinical neuroscience · 2019Review
- Mapping the collaterome for precision cerebrovascular health: Theranostics in the continuum of stroke and dementia.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018Review
- Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease.Journal of personalized medicine · 2018Review
- Cerebrovascular-Reactivity Mapping Using MRI: Considerations for Alzheimer's Disease.Frontiers in aging neuroscience · 2018Article
- Mini-Symposium: Energy Demand and Energy Supply in Alzheimer's Disease - Introduction.Brain pathology (Zurich, Switzerland) · 2016Article
- Transcranial photobiomodulation (laser) therapy for cognitive impairment: A review of molecular mechanisms and potential application to canine cognitive dysfunction (CCD).Open veterinary journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular and cerebrovascular diseases are major risk factors in the development of cognitive impairment and Alzheimer's disease (AD). These cardio-cerebral disorders promote a variety of vascular risk factors which in the presence of advancing age are prone to markedly reduce cerebral perfusion and create a neuronal energy crisis. Long-term hypoperfusion of the brain evolves mainly from cardiac structural pathology and brain vascular insufficiency. Brain hypoperfusion in the elderly is strongly associated with the development of mild cognitive impairment (MCI) and both conditions are presumed to be precursors of Alzheimer dementia. A therapeutic target to prevent or treat MCI and consequently reduce the incidence of AD aims to elevate cerebral perfusion using novel pharmacological agents. As reviewed here, the experimental pharmaca include the use of Rho kinase inhibitors, neurometabolic energy boosters, sirtuins and vascular growth factors. In addition, a compelling new technique in laser medicine called photobiomodulation is reviewed. Photobiomodulation is based on the use of low level laser therapy to stimulate mitochondrial energy production non-invasively in nerve cells. The use of novel pharmaca and photobiomodulation may become important tools in the treatment or prevention of cognitive decline that can lead to dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.